What the Wegovy dose stages actually look like — week by week

You've just been prescribed 0.25 mg and you're wondering when anything will happen

The first stage often puzzles people. You inject 0.25 mg once a week and, for many, the scales barely shift. That's expected. The 0.25 mg stage exists to acclimatise your system to semaglutide, it keeps nausea, vomiting and other gastrointestinal effects to a minimum while your body gets used to the medicine. Think of it less as treatment and more as preparation for treatment.

After four weeks, most people move to 0.5 mg. Again, the prescriber is watching how well you're tolerating things. If side effects are significant, staying at 0.25 mg for another four weeks is entirely reasonable. The starting dose of Wegovy is never the dose at which the published weight-loss results were measured, those came from people who reached and held 2.4 mg. If you want to understand what the dosages for Wegovy are and how each one fits into the overall plan, the NHS medicines information for semaglutide confirms this titration structure and explains why each step matters for safety and tolerability. NHS guidance on semaglutide is worth bookmarking for the duration of your treatment.

One practical note: if you miss a dose during this early stage, don't double up on your next injection. Contact your prescriber or refer to the patient information leaflet supplied with your pen. Getting the habit of weekly injections established (same day, same rough time) makes the whole journey smoother.

The middle stages: 1.0 mg and 1.7 mg, where most people start to notice a real shift

By the time someone reaches 1.0 mg (roughly week nine if titration goes smoothly) appetite suppression tends to become noticeably stronger. GLP-1 receptor agonists work partly by slowing how quickly the stomach empties and partly by signalling fullness to the brain, and at 1.0 mg those effects are more pronounced than at the starter dose. Nausea is still possible, particularly in the days after each injection, but it often settles into a pattern that people learn to manage: injecting in the evening, eating smaller meals, staying well hydrated.

The 1.7 mg stage sits between 1.0 mg and the 2.4 mg maintenance dose. It's a bridging step, allowing the body one more gradual adjustment before the full maintenance level. Some prescribers keep patients at 1.7 mg longer if GI side effects are still troublesome; others move through on schedule. There is no clinical shame in a slower titration. A full breakdown of how each strength is structured is covered in our guide to Wegovy dosages if you want to read the numbers alongside the context.

Fatigue and headaches are reported at these middle stages, often tied to eating less than usual. Protein intake and fluid levels matter here, discuss a basic plan with your prescriber or a dietitian rather than improvising. People are often curious about what dosages Wegovy comes in and which pen strengths are available at each stage; the cost of Wegovy across these stages is something many people think about too, and you can find an honest breakdown of what private treatment typically involves on the Wegovy cost page.

Reaching 2.4 mg: what maintenance actually means

The 2.4 mg dose is where the STEP 1 trial (a 68-week study published in the New England Journal of Medicine) recorded an average weight reduction of around 15% in adults with obesity. That figure comes from people who reached and sustained this maintenance dose alongside lifestyle changes, so it's the benchmark worth understanding. The STEP 1 trial paper is freely available if you want to read the methodology.

Maintenance doesn't mean the work is done, it means the dose is stable and the focus shifts to sustaining the habits built during titration. Side effects at 2.4 mg can flare briefly after moving up from 1.7 mg, then typically settle. Weight loss tends to continue for several months before plateauing for many people. NICE's guidance on semaglutide for weight management (Technology Appraisal TA875) recommends reviewing treatment if less than 5% weight loss has been achieved after six months at the maintenance dose, so the 2.4 mg stage is also the point at which clinical review matters most.

A note on the newer 7.2 mg dose: the MHRA approved this higher maintenance level, with a dedicated single-dose pen confirmed in April 2026. It's intended for adults with a BMI of 30 or above. Titration still starts at 0.25 mg, reaching 7.2 mg means completing the standard stages first. Our Wegovy overview covers what the approval means in practice. Specific dose availability is confirmed at consultation; a prescriber decides whether 7.2 mg is appropriate for any individual.

When the schedule doesn't go to plan, and what that tells you

Real titration rarely follows the textbook timeline exactly. Someone might sail through to 2.4 mg in twenty weeks; another person stays at 1.0 mg for twelve weeks because their nausea is persistent. Both are clinically valid. The staged schedule exists precisely because there is no universal tolerance threshold, prescribers use it as a framework, not a timetable.

If you transfer to Wegovy from another GLP-1 treatment, your prescriber may start you at a different stage based on your history, though evidence of your current dose and treatment would be required. Our clinical team's approach to this is outlined on the about us page. For any questions about your specific situation, the FAQs cover the most common concerns, and the team is reachable via contact seven days a week.

If you're at any stage and experiencing severe, persistent stomach pain (especially pain that radiates to the back) seek medical attention promptly. That pattern can indicate pancreatitis, which the MHRA flagged as a known but infrequent serious side effect in a Drug Safety Update in January 2026. Most people complete titration without anything like that, but knowing the signals matters. If you're ready to discuss which dose stage is right for where you are now, speak to our prescribers, a GPhC-registered clinician reviews every consultation the same day.